No headlines found.
Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform
PRNewswire (Tue, 7-Jan 8:00 AM ET)
Coeptis Therapeutics Announces Reverse Stock Split
PRNewswire (Fri, 27-Dec 8:15 AM ET)
PRNewswire (Thu, 26-Dec 8:15 AM ET)
PRNewswire (Tue, 3-Dec 8:15 AM ET)
PRNewswire (Thu, 7-Nov 8:07 AM ET)
PRNewswire (Thu, 24-Oct 8:07 AM ET)
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Coeptis Therapeutics Holdings trades on the NASDAQ stock market under the symbol COEP.
As of January 17, 2025, COEP stock price declined to $9.27 with 43,274 million shares trading.
COEP has a market cap of $22.29 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that COEP belongs to (by Net Assets): VXF.
COEP has underperformed the market in the last year with a return of -14.2%, while SPY returned +28.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in COEP shares. However, COEP has outperformed the market in the last 3 month and 2 week periods, returning +132.9% and +62.1%, while SPY returned +3.0% and +1.0%, respectively. This indicates COEP has been having a stronger performance recently.
COEP support price is $8.11 and resistance is $11.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COEP shares will trade within this expected range on the day.